Skip to content

menu

DLA Piper logo
DLA Piper logo
HomeAboutContactWhat's NewEducation Resources
Search
Close

Cultivate

Legal insights from leading hemp and CBD lawyers

What's NewEducation ResourcesLitigation TrackerSub-MenuMislabeling & Advertising ClaimsMedical & Health ClaimsShareholder LitigationDietary Supplement ClaimsLabor & Employment ClaimsIntellectual PropertyProduct Liability Claims

Melissa Gilmore

Subscribe to Melissa Gilmore's Posts

A Green Light for Canna-Research? Medical Marijuana and CBD Research Bill on the Cusp

By Jarred Reiling, Melissa Gilmore & Jae Kim on August 10, 2022
Posted in Regulatory

The House has passed a revised version of the Medical Marijuana and Cannabidiol Research Expansion Act, HR 8454, sending it back to the Senate for action. With previous bipartisan…

Continue Reading A Green Light for Canna-Research? Medical Marijuana and CBD Research Bill on the Cusp

Blog Managers

Photo of Christopher GismondiChristopher GismondiOf Counsel
Photo of Jae KimJae KimAssociate, FDA Regulatory Group
Photo of Jarred ReilingJarred ReilingOf Counsel
Photo of Kelsey TavaresKelsey TavaresAssociate

Blog Authors Show/Hide

  • Kristin Beale
  • Stuart Brown
  • Christian Chessman
  • Maggie Craig
  • Stefanie Fogel
  • Melissa Gilmore
  • Christopher Gismondi
  • Jeffrey Hare
  • Jae Kim
  • Sharon Lindan Mayl
  • Wendy Michael
  • Jarred Reiling
  • Kelsey Tavares

Additional Topics

Archives

Subscribe by Email

Stay Connected

RSS Twitter LinkedIn Facebook YouTube Instagram Slideshare WeChat

Links & Resources

  • DLA Piper's Hemp and Hemp Regulated Products/CBD sector

Recent Posts

  • HHS to DEA: Marijuana Should Be Schedule III – What This Means for The Cannabis Industry
  • Two hemp-derived CBD bills are re-introduced despite FDA’s call for a different legislative fix
  • FDA seems willing to make room for a drug ingredient in a supplement, but what does that mean for CBD? NAC and the Drug Exclusion Clause of 201(ff)
  • A Green Light for Canna-Research? Medical Marijuana and CBD Research Bill on the Cusp
  • Federal Agencies’ Current Positions on Hemp-Derived CBD Products
Legal NoticesPrivacy PolicyCookie Policydlapiper.com
RSS Twitter LinkedIn Facebook YouTube Instagram Slideshare WeChat
Copyright © 2025, DLA Piper. DLA Piper is a global law firm operating through various separate and distinct legal entities. For further information about these entities and DLA Piper’s structure, please refer to the Legal Notices page of this website. All rights reserved. Attorney advertising.
Law blog design & platform by LexBlog LexBlog Logo